Biostock Interview: Chordate Board Member presents Ozilia at Feminvest

Biostock interviews Chordate board member Caroline Brandberg, who last week participated at Feminvest’s investor congress in Oslo. During the event, she presented Chordate’s migraine treatment, Ozilia.

“Migraine is one of the leading conditions among women. To address this, more treatment options are needed, which must be made available and affordable in order for all women to have access to adequate care.”

Read the full interview

More posts

For questions about Chordate’s share price or other investment-related topics, please see if the answer is here.

For questions about the medical effects of Ozilia® Migraine, please see if the answer is here.

To get in touch with Chordate regarding other questions, use the adjecent form. We do our best to respond as quickly as possible.

Please note that the MAR rules (Market Abuse Regulation) prohibits us from providing information to individual inquirers regarding matters of the company’s share, share price, economy and financials, commercial and scientific activities, and other information that potentially can alter the Market valuation of the traded share. We refer in general to the public information published by the company for such questions. Hence, emails with such questions will not be responded to individually.

Contact us

  • This field is for validation purposes and should be left unchanged.

The information is handled according to our privacy policy